CD8A and neoplasm: Therefore we decided to challenge and treat these poorly immunogenic CT26WT colon carcinoma cells with aFP and anti-PD-1 inhibitor, which boosts the function of CD8+ T cells by blocking the PD-1/ PD-L1 pathway14–16, to confirm if aFP can be used for induction of anti-tumor immunity and promote regression of a remote and untreated tumor in the clinical relevant situation, which is in marked contrast to the current applications of FP.